Penserra Capital Management LLC Adaptimmune Therapeutics PLC Transaction History

Penserra Capital Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 15, 2022	SELL	$3.5 - $5.68 $10,972 - $17,806	-3,135 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$3.44 - $6.37 $103 - $191	30 Added 0.97%	3,135 $16,000
Q2 2021 Aug 12, 2021	BUY	$3.86 - $5.78 $19 - $28	5 Added 0.16%	3,105 $13,000
Q1 2021 May 13, 2021	SELL	$4.9 - $6.83 $392 - $546	-80 Reduced 2.52%	3,100 $16,000
Q4 2020 Feb 12, 2021	BUY	$4.0 - $9.2 $12,720 - $29,255	3,180 New	3,180 $17,000

150M

60.8K

5.8K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $114M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Penserra Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Penserra Capital Management LLC with notifications on news.